Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss

Articles From: Air Products's 2nd-Quarter Net Drops 1.9%; Co Slashes Year View to UBS Updates Short-Term Gold Price Targets

This site contains about 63,386 documents.
View by:
Title  |  Date  |  Author  |  Collection  |  Interest  |  Popularity
Page:   1   400   500   600   700   800   900   1,000   1,100   1,200   1,380   1,390   1,400   1,410   1,420   1,430   1,440   1,450   1,460   1,468   1,469   1,470   1,471   1,472   1,473   1,474   1,475   1,476   1,477   1,478   1,479   1,480   1,481   1,482   1,483   1,484   1,485   1,486   1,487   1,488   1,489   1,490   1,491   1,492   1,493   1,494   1,495   1,496   1,497   1,500   1,510   1,520   1,530   1,540   1,550   1,560   1,570   1,580   1,600   1,700   1,800   1,900   2,000   2,100   2,113 

2013/4/23
Air Products's 2nd-Quarter Net Drops 1.9%; Co Slashes Year View
Air Products & Chemicals Inc.'s (APD) fiscal-second quarter earnings edged down 1.9% as the industrial-gas maker reported a rise in certain costs, while its income tax provision surged.
View more Air Products's 2nd-Quarter Net Drops 1.9%; Co Slashes Year View analysis
Sign-up for Air Products's 2nd-Quarter Net Drops 1.9%; Co Slashes Year View investment picks
2013/4/23
II-VI Incorporated Reports Fiscal Third Quarter Earnings
PITTSBURGH, April 23, 2013 (GLOBE NEWSWIRE) -- II-VI Incorporated (Nasdaq:IIVI) today reported results for its third fiscal quarter ended March 31, 2013.
View more II-VI Incorporated Reports Fiscal Third Quarter Earnings analysis
Sign-up for II-VI Incorporated Reports Fiscal Third Quarter Earnings investment picks
2013/4/23
Nidec Resolves to Make Nidec Copal Corp., Nidec Tosok Corp. and Nidec Seimitsu Corp. Its Wholly Owned Subsidiaries
KYOTO, Japan, April 23, 2013 (GLOBE NEWSWIRE) -- Nidec Corporation ("Nidec") (NYSE:NJ) announced today that, at its board meeting held today, it has resolved to implement share exchange transactions to make Nidec Copal Corporation ("Nidec Copal"), Nidec Tosok Corporation ("Nidec Tosok") and Nidec Seimitsu Corporation ("Nidec Seimitsu") wholly owned subsidiaries of Nidec and agreed accordingly with the respective companies.
View more Nidec Resolves to Make Nidec Copal Corp., Nidec Tosok Corp. and Nidec Seimitsu Corp. Its Wholly Owned Subsidiaries analysis
Sign-up for Nidec Resolves to Make Nidec Copal Corp., Nidec Tosok Corp. and Nidec Seimitsu Corp. Its Wholly Owned Subsidiaries investment picks
2013/4/23
Italy's Safilo Earnings Up Despite Loss of Armani License
ROME --Italian eyewear maker Safilo Group SpA (SFL.MI) whose brands include Gucci and Hugo Boss posted an increase in first-quarter earnings despite losing its coveted license to make sunglasses for Giorgio Armani SpA .
View more Italy's Safilo Earnings Up Despite Loss of Armani License analysis
Sign-up for Italy's Safilo Earnings Up Despite Loss of Armani License investment picks
2013/4/23
Kone Upgrades Guidance After Strong Order Intake
Finnish escalator and lift maker Kone Oyj (KNEBV.HE) Tuesday posted a 15% rise in first-quarter net profit and upgraded its full-year guidance due to strong order intake in Asia-Pacific and North America .
View more Kone Upgrades Guidance After Strong Order Intake analysis
Sign-up for Kone Upgrades Guidance After Strong Order Intake investment picks
2013/4/23
Nidec Announces Differences Between Financial Projection and Actual Results for Fiscal Year Ended March 31, 2013 and Revision to Year-End Dividend Forecast
KYOTO, Japan, April 23, 2013 (GLOBE NEWSWIRE) -- Nidec Corporation (the "Company") (NYSE:NJ) today announced differences between its financial forecast for the year ended March 31, 2013 (announced on January 24, 2013) and the actual financial results released today.
View more Nidec Announces Differences Between Financial Projection and Actual Results for Fiscal Year Ended March 31, 2013 and Revision to Year-End Dividend Forecast analysis
Sign-up for Nidec Announces Differences Between Financial Projection and Actual Results for Fiscal Year Ended March 31, 2013 and Revision to Year-End Dividend Forecast investment picks
2013/4/23
Nidec Announces Financial Results for Fiscal Year Ended March 31, 2013
KYOTO, Japan, April 23, 2013 (GLOBE NEWSWIRE) -- Nidec Corporation (NYSE:NJ) today announced its consolidated results under U.S.GAAP for the fiscal year ended March 31, 2013.
View more Nidec Announces Financial Results for Fiscal Year Ended March 31, 2013 analysis
Sign-up for Nidec Announces Financial Results for Fiscal Year Ended March 31, 2013 investment picks
2013/4/23
Potlatch Reports First Quarter 2013 Results
SPOKANE, Wash., April 23, 2013 (GLOBE NEWSWIRE) -- Potlatch Corporation (Nasdaq:PCH) today reported financial results for the first quarter ended March 31, 2013.
View more Potlatch Reports First Quarter 2013 Results analysis
Sign-up for Potlatch Reports First Quarter 2013 Results investment picks
2013/4/23
Descartes' Telematics Customer New World First Bus and Citybus Win Technology Innovation Award
Descartes Solution Provides Highly-Accurate Positioning and Arrival Time Notification WATERLOO, Ontario, April 23, 2013 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that its customer, New World First Bus Services Limited ("NWFB") and Citybus Limited, won the "Best Public Service Application Grand Award" and "Best Public Service Application (Transformation) Gold Award" in The Hong Kong ICT Awards 2013.
View more Descartes' Telematics Customer New World First Bus and Citybus Win Technology Innovation Award analysis
Sign-up for Descartes' Telematics Customer New World First Bus and Citybus Win Technology Innovation Award investment picks
2013/4/23
FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Sucampo’s supplemental new drug application (sNDA) for AMITIZA ® (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.
View more FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain analysis
Sign-up for FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain investment picks
2013/4/23
UBS slashes gold target, cites soured sentiment
Investment bank UBS on Tuesday updated its short-term price targets for gold following the precious metal's recent volatility.
View more UBS slashes gold target, cites soured sentiment analysis
Sign-up for UBS slashes gold target, cites soured sentiment investment picks
2013/4/23
U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
Among the companies with shares expected to actively trade in Tuesday's session are are Netflix Inc. (NFLX), Rent-A- Center Inc. (RCII), Veeco Instruments Inc. (VECO) Netflix swung to a first-quarter profit as the movie-subscription company continued to add Internet subscribers and unveiled a plan that will allow users to simultaneously stream four videos.
View more U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH analysis
Sign-up for U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH investment picks
2013/4/23
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™
Merck (NYSE: MRK) , known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.
View more Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™ analysis
Sign-up for Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™ investment picks
2013/4/23
DuPont's net more than doubles on discontinued ops
DuPont Co.'s DD DD first-quarter earnings more than doubled as the diversified U.S. manufacturer reported a larger profit from discontinued operations than in the year-ago period, while revenue climbed.
View more DuPont's net more than doubles on discontinued ops analysis
Sign-up for DuPont's net more than doubles on discontinued ops investment picks
2013/4/23
BP to Invest 5Bln Rand in S Africa, Mozambique in Next 5 Years
JOHANNESBURG-BP Group (BP) Tuesday said the energy company will invest more than 5 billion rand ( $540 million ) in South Africa and Mozambique over the next five years.
View more BP to Invest 5Bln Rand in S Africa, Mozambique in Next 5 Years analysis
Sign-up for BP to Invest 5Bln Rand in S Africa, Mozambique in Next 5 Years investment picks
2013/4/23
IDT Announces Industry’s First Glitch-Free™ RF Digital Step Attenuator with Integrated Blocking Capacitors
Integrated Device Technology, Inc. ( IDT ® ) (NASDAQ: IDTI) , the Analog and Digital Company™ delivering essential mixed-signal semiconductor solutions, today announced the industry’s first Glitch-Free™ radio frequency (RF) digital step attenuator (DSA) with integrated blocking capacitors.
View more IDT Announces Industry’s First Glitch-Free™ RF Digital Step Attenuator with Integrated Blocking Capacitors analysis
Sign-up for IDT Announces Industry’s First Glitch-Free™ RF Digital Step Attenuator with Integrated Blocking Capacitors investment picks
2013/4/23
Akamai Releases Fourth Quarter 2012 'State of the Internet' Report
CAMBRIDGE, Mass.
View more Akamai Releases Fourth Quarter 2012 'State of the Internet' Report analysis
Sign-up for Akamai Releases Fourth Quarter 2012 'State of the Internet' Report investment picks
2013/4/23
Superconductor Technologies Announces the Receipt of Purchase Orders From Leading Multinational Industrial Companies for Conductus 2G HTS Wire
AUSTIN, Texas, April 23, 2013 (GLOBE NEWSWIRE) -- Superconductor Technologies Inc. (STI) (Nasdaq:SCON) , a world leader in the development and production of high temperature superconducting (HTS) materials and associated technologies, announces that it has recently received purchase orders from multiple customers for its Conductus ® 2G HTS wire.
View more Superconductor Technologies Announces the Receipt of Purchase Orders From Leading Multinational Industrial Companies for Conductus 2G HTS Wire analysis
Sign-up for Superconductor Technologies Announces the Receipt of Purchase Orders From Leading Multinational Industrial Companies for Conductus 2G HTS Wire investment picks
2013/4/23
Beazer Homes Names Ekaterina Schwallie Vice President, Treasurer and Financial Planning and Analysis
Beazer Homes USA, Inc. (NYSE: BZH) ( www.beazer.com ) today announced the promotion and appointment of Ekaterina “Katya” Schwallie to Vice President, Treasurer and Financial Planning and Analysis, assuming an expanded role after Jeffrey Hoza, the Company’s former Treasurer, was recently named Atlanta Division President.
View more Beazer Homes Names Ekaterina Schwallie Vice President, Treasurer and Financial Planning and Analysis analysis
Sign-up for Beazer Homes Names Ekaterina Schwallie Vice President, Treasurer and Financial Planning and Analysis investment picks
2013/4/23
Silicon Motion Announces Quarterly Dividend
TAIPEI, Taiwan, April 23, 2013 (GLOBE NEWSWIRE) -- Silicon Motion Technology Corporation (Nasdaq:SIMO) ("Silicon Motion" or the "Company"), a global leader in designing and marketing NAND flash controllers for solid state storage devices and specialty RF IC solutions for mobile devices, announces today its next quarterly cash dividend.
View more Silicon Motion Announces Quarterly Dividend analysis
Sign-up for Silicon Motion Announces Quarterly Dividend investment picks
2013/4/23
CIT Reports First Quarter 2013 Net Income of $163 Million ($0.81 Per Diluted Share)
CIT Group Inc. (NYSE: CIT) , a leading provider of financing and advisory services to small businesses and middle market companies, today reported net income of $163 million, $0.81 per diluted share, for the first quarter of 2013, compared to a net loss of $427 million, ($2.13) per diluted share, for the first quarter of 2012.
View more CIT Reports First Quarter 2013 Net Income of $163 Million ($0.81 Per Diluted Share) analysis
Sign-up for CIT Reports First Quarter 2013 Net Income of $163 Million ($0.81 Per Diluted Share) investment picks
2013/4/23
Veris Gold Corp. Announces New Team Members
Veris Gold Corp.
View more Veris Gold Corp. Announces New Team Members analysis
Sign-up for Veris Gold Corp. Announces New Team Members investment picks
2013/4/23
Veris Gold Corp. Announces New Team Members
Toronto Stock Exchange: VG VANCOUVER , April 23, 2013 /PRNewswire/ - Veris Gold Corp.
View more Veris Gold Corp. Announces New Team Members analysis
Sign-up for Veris Gold Corp. Announces New Team Members investment picks
2013/4/23
National Technical Systems Wins New Contract from Sandia National Laboratories
Continues Development of Harvester Project for Monitoring Radiation in the Atmosphere CALABASAS, Calif.
View more National Technical Systems Wins New Contract from Sandia National Laboratories analysis
Sign-up for National Technical Systems Wins New Contract from Sandia National Laboratories investment picks
2013/4/23
BioCryst to Announce First Quarter 2013 Financial Results May 7
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2013 financial results will be released on Tuesday, May 7, 2013.
View more BioCryst to Announce First Quarter 2013 Financial Results May 7 analysis
Sign-up for BioCryst to Announce First Quarter 2013 Financial Results May 7 investment picks
2013/4/23
EARNINGS FORECAST TABLE: AstraZeneca 1Q 2013
FRANKFURT --The following is a summary of analysts' forecasts for AstraZeneca plc (AZN) first-quarter results, based on a poll of seven analysts conducted by Dow Jones Newswires (figures in million dollars, EPS and dividend in dollar, target price in pence, according to IFRS). Earnings figures are scheduled to be released April 25 .
View more EARNINGS FORECAST TABLE: AstraZeneca 1Q 2013 analysis
Sign-up for EARNINGS FORECAST TABLE: AstraZeneca 1Q 2013 investment picks
2013/4/23
Sainsbury's Market Share Rises to 16.9%, Tesco Slips to 29.9%
LONDON --Continuing recent trends J Sainsbury PLC (SBRY.LN) was the only one of the top four U.K. supermarkets to gain market share in the latest 12 weeks ended April 14 , while Tesco PLC (TSCO.LN) saw its share slide further to 29.9%. MAIN FACTS: -Tesco market share for 12 weeks ended April 14 29.9% (12 weeks ended April 15, 2012 : 30.7%) - J Sainsbury market share 16.9% (2012: 16.6%) -Asda market share 17.5% (2012: 17.6%) - Wm Morrison Supermarkets PLC (MRW.LN) market share 11.5% (2012: 11.9%) -Aldi and Lidl's joint market share 6.4% (2012: 5.5%); Aldi's share 3.4% (2012: 2.7%); Lidl's share 3.0% (2012: 2.8%). -Waitrose market share 4.9% (2011: 4.5%). -Grocery inflation stands at 3.8% for the 12 weeks ending April 14 .
View more Sainsbury's Market Share Rises to 16.9%, Tesco Slips to 29.9% analysis
Sign-up for Sainsbury's Market Share Rises to 16.9%, Tesco Slips to 29.9% investment picks
2013/4/23
Enanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta’s lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta’s proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, (ILC), which is the 48 th Annual Meeting of the European Association for the Study of the Liver (EASL) taking place in Amsterdam April 24-28, 2013.
View more Enanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL analysis
Sign-up for Enanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL investment picks
2013/4/23
New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1
- 96 percent of treatment-naive patients and 93 percent of prior null responders treated with AbbVie's investigational IFN-free, triple-DAA combination therapy achieve SVR24 - Additional analyses looks at response rates in patients with differing baseline factors including gender, viral load and fibrosis stage AMSTERDAM , April 23, 2013 /PRNewswire/ --  (NYSE: ABBV)   – Results from "Aviator,"  AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types.
View more New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1 analysis
Sign-up for New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1 investment picks
2013/4/23
UBS Updates Short-Term Gold Price Targets
Investment bank UBS on Tuesday updated its short-term price targets for gold following the precious metal's recent volatility.
View more UBS Updates Short-Term Gold Price Targets analysis
Sign-up for UBS Updates Short-Term Gold Price Targets investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Articles From: Air Products's 2nd-Quarter Net Drops 1.9%; Co Slashes Year View to UBS Updates Short-Term Gold Price Targets
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.